6 research outputs found
Reproductive Performance of Barki Rams Fed on Different Omega-6: Omega-3 Ratios
The current experiment intended to investigate the impact of various dietary omega- 6/ omega -3 fatty acids ratios (FAs) on the reproductive performance and serum lipid profile in male Barki sheep over two months' experimental period. Twelve males were randomly allotted into 4 equal groups receiving 4 different ratios of omega-6/ omega- 3 FAs including 5.40 (higher ratio, HR), 4.56 (medium ratio, MR), 3.13 (lower ratio, LR) and 1.76 (very low ratio, VLR):1. Feeding rams on diets with HR or VLR did not exhibit substantial impact on the sperm motility, sperm viability and testosterone hormone, however these parameters were non-significantly improved in the MR and LR- fed rams. The semen volume was significantly increased (P < 0.05) with the MR in comparison with the remaining groups. Serum biochemical parameters, including total lipids, HDL concentrations did not exhibit significant differences (P> 0.05) among the different ratios. VLR- fed rams showed the higher serum total cholesterol, triglyceride, LDL and VLDL (P< 0.05), while the MR fed rams showed the highest CHO/HDL ratio (P< 0.05) in comparison with the other ratios. In summary, Barki rams fed different omega-6/ omega- 3 PUFA ratios (5.4, 4.56, 3.13 and 1.76:1) containing diets exhibited no significant difference in their reproductive performance parameters, however the medium (4.56:1) and low (3.13:1) ratios showed potential improving effect
Pan-African magmatism in the Wadi El-Imra district, Central Eastern Desert, Egypt: geochemistry and tectonic environment
Synthesis, thermal, spectral, antimicrobial and cytotoxicity profile of the Schiff bases bearing pyrazolone moiety and their Cu(II) complexes
Development and implementation of the AIDA International Registry for Patients with VEXAS syndrome
Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome
The aim of this paper is to present the AutoInflammatory Disease Alliance (AIDA) international Registry dedicated to Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome, describing its design, construction, and modalities of dissemination
Development and implementation of the AIDA International Registry for patients with Behçet's disease
Purpose of the present paper is to point out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients with Behcet's disease (BD). The Registry is a clinical physician-driven non-population- and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental and socioeconomic information from BD patients; the Registry is based on the Research Electronic Data Capture (REDCap) tool, which is thought to collect standardised information for clinical real-life research, and has been realised to change over time according to future scientific acquisitions and potentially communicate with other existing and future Registries dedicated to BD. Starting from January 31st, 2021, to February 7th, 2022, 110 centres from 23 countries in 4 continents have been involved. Fifty-four of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 175 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 5993 fields organised into 16 instruments, including patient's demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. The development of the AIDA International Registry for BD patients will facilitate the collection of standardised data leading to real-world evidence, enabling international multicentre collaborative research through data sharing, international consultation, dissemination of knowledge, inclusion of patients and families, and ultimately optimisation of scientific efforts and implementation of standardised care. Trial registration NCT05200715 in 21/01/2022